Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T20:49:24.483Z Has data issue: false hasContentIssue false

17 - Kidney

Published online by Cambridge University Press:  23 December 2009

Jason Lester
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
John Wagstaff
Affiliation:
Consultant, Medical Oncologist, Singleton Hospital, Sketty, Swansea, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

Cancer of the kidney represents 3% of adult malignancies. There are about 6500 new cases per year diagnosed in England and Wales, occurring most commonly between the ages of 50 and 70 years. Men are more frequently affected than women. More than 30% of patients present with metastatic disease. The majority of malignant tumours are adenocarcinomas, arising from the proximal renal tubular epithelium. These tumours were previously called hypernephroma because it was believed that they originated from adrenal rests, but they are correctly termed renal cell carcinoma (RCC). Transitional cell carcinoma of the renal pelvis accounts for 5% of all renal malignancies, and is covered separately at the end of the chapter.

Types of kidney tumour

Kidney tumours can be benign, malignant primary or metastatic. Benign tumours include cysts (simple, complex, multiple), inflammatory (infection, infarction), adenoma, and oncocytoma. Malignant primary tumours include RCC, lymphoma, sarcoma and renal pelvis tumours (5% of malignant renal cancers arise from the renal pelvis, and more than 90% of these are transitional cell carcinoma).

Anatomy

The kidneys are retroperitoneal structures that lie between the 11th rib and the transverse process of the 3rd lumbar vertebral body, each approximately 11 cm in length, the right lying slightly lower than the left. Each kidney is surrounded by perinephric fat which in turn is covered by Gerota's fascia. The right kidney abuts the liver and stomach and the left, the spleen, stomach, and pancreas.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aso, Y. and Homma, Y. (1992). A survey of incidental renal cell carcinoma in Japan. J. Urol., 147, 340–3.CrossRefGoogle ScholarPubMed
Atkins, M., Regan, M., McDermott, D.et al. (2005). Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res., 11, 3714–21.CrossRefGoogle ScholarPubMed
Atzpodien, J., Kirchner, H., Illiger, H. J.et al. (2001). IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer, 85, 1130–6.CrossRefGoogle ScholarPubMed
Bell, E. T. (1950). Renal Diseases, 2nd edn. Philadelphia, PA: Lea and Febiger.Google Scholar
Bosniak, M. A. (1986). The current radiological approach to renal cysts. Radiology, 158, 1–10.CrossRefGoogle ScholarPubMed
Clark, J., Atkins, M., Urba, W.et al. (2003). Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol., 21, 3133–40.CrossRefGoogle ScholarPubMed
Coppin, C., Porzsolt, F., Awa, A.et al. (2005). Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev., 1, CD001425.Google Scholar
Escudier, B., Szczylik, C., Eisen, T.et al. (2005). Randomized phase III trial of the Raf kinase and vascular endothelial growth factor receptor inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (renal cell carcinoma). Proc. Am. Soc. Clin. Oncol., 23, 380s.Google Scholar
Finney, R. (1973). Radiotherapy in the treatment of hypernephroma: a clinical trial. Br. J. Urol., 45, 26–40.CrossRefGoogle ScholarPubMed
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A.et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med., 345, 1655–9.CrossRefGoogle ScholarPubMed
Fuhrman, S. A., Lasky, L. C., Limas, C.et al. (1982). Prognostic significance of morphological parameters in renal cell carcinoma. Am. J. Surg. Pathol., 6, 655–63.CrossRefGoogle Scholar
Hudes, G., Carducci, M., Tomczak, P.et al. (2006). A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv renal cell carcinoma). J. Clin. Oncol., 24 (18 Suppl.), LBA4.Google Scholar
Jocham, D., Richter, A., Hoffmann, L.et al. (2004). Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, 363, 594–9.CrossRefGoogle ScholarPubMed
Kjaer, M. (1988). The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat. Rev., 15, 195–209.CrossRefGoogle ScholarPubMed
Kjaer, M., Frederiksen, P. L. and Engelholm, S. A.et al. (1987). Postoperative radiotherapy in stage II and III renal adenocarcinoma: a randomised trial by the Copenhagen Renal Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys., 13, 665–72.CrossRefGoogle Scholar
Kovacs, G., Akhtar, M., Beckwith, B. J.et al. (1997). The Heidelberg classification of renal cell tumours. J. Pathol., 183, 131–3.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
Mekhail, T. M., Abou-Jawde, R. M., Boumerhi, G.et al. (2005). Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol., 23, 832–41.CrossRefGoogle ScholarPubMed
Messing, E., Manola, J., Wilding, G.et al. (2003). Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol., 21, 1214–22.CrossRefGoogle ScholarPubMed
Mickisch, G. H., Garin, A., Poppel, H.et al. (2001). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358, 966–70.CrossRefGoogle ScholarPubMed
Montie, J. E., Stewart, B. H., Straffon, R. A.et al. (1977). The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol., 117, 272–5.CrossRefGoogle ScholarPubMed
Motzer, R. J., Hutson, T. E., Tomczak, P.et al. (2006a). Phase III randomised trial of sunitinib maleate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol., 24 (18 Suppl.), LBA3.Google Scholar
Motzer, R. J., Michaelson, M. D., Redman, B. G.et al. (2006b). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 24, 16–24.CrossRefGoogle Scholar
Murphy, W. M., Beckwith, J. B. and Farrow, G. M. (1994). Tumors of the kidney, bladder, and related urinary structures. In: Atlas of Tumor Pathology, 3rd edn. Bethesda, MD: Armed Force Institute of Pathology.Google Scholar
Dea, M. J., Zincke, H., Utz, D. C.et al. (1978). The treatment of renal cell carcinoma with solitary metastasis. J. Urol., 120, 540–2.Google Scholar
Tada, S., Yamagishi, J., Kobayashi, H.et al. (1983). The incidence of simple renal cyst by computed tomography. Clin. Radiol., 34, 437–9.CrossRefGoogle ScholarPubMed
International Union Against Cancer. (2002). In tumour nodes metastases Classification of Malignant Tumours, 6th edn. Ed. Sobin, L. H. and Wittekind, Ch.. New York: Wiley-Liss, pp. 193–5.Google Scholar
Yagoda, A., Abi-Rached, B., Petrylak, D.et al. (1995). Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin. Oncol., 22, 42–60.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Kidney
    • By Jason Lester, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Wagstaff, Consultant, Medical Oncologist, Singleton Hospital, Sketty, Swansea, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.018
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Kidney
    • By Jason Lester, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Wagstaff, Consultant, Medical Oncologist, Singleton Hospital, Sketty, Swansea, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.018
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Kidney
    • By Jason Lester, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Wagstaff, Consultant, Medical Oncologist, Singleton Hospital, Sketty, Swansea, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.018
Available formats
×